Natco seeks indian compulsory licence for Nexavar
This article was originally published in Scrip
There is more pressure building up over Bayer's anticancer Nexavar (sorafenib tosylate) in India. The product, which is already a subject of intense litigation in India, is now expected to serve as a litmus test for India's resolve or otherwise in invoking compulsory licensing provisions for life-saving drugs currently inaccessible to many.
You may also be interested in...
Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.
The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.